Off-patent Rx leads fibromyalgia category by ProQuest

VIEWS: 9 PAGES: 2

More Info
									IN FOCUS

Off-patent Rx leads fibromyalgia category
As the number of FDA-                                                                                                         generics will decrease in the next
approved fibromyalgia thera-          Brand share by line of therapy                                                          two years, presumably as these
pies has grown, so has patient        First-line prescriptions for fibromyalgia among PCPs, rheumatologists                   physicians turn more frequently
hope for relief from the ail-                        40%                                                                      to drugs with regulatory approv-
                                      40
ment. however, the condition                 35%
                                                                                      37%                                     al in early lines of treatment.
is still not well understood by       35                            33% 33%     32%            32% 32%                           still, more education could
the medical community overall,        30                                                                                      help boost brand share. On whom
hampering uptake of branded           25
                                                                                                                              should marketers target their
                                                                                                                    21%
drugs approved for the disorder.                                                                                              educational efforts? Accord-
                                      20                                                                      18%
A new report suggests that bet-                                                                                               ing to Decision resources, a
ter training for internists, who      15                                                                                      focused effort on reducing the
are on the front lines of diagno-     10                                                                                      number of visits that an internist
sis and treatment, could help.         5                                                                                      needs to diagnose fibromyalgia
   the problem starts in the           0                                                                                      could accelerate prescriptions
exam room. Among primary                     Amitriptyline    Cyclobenzaprine   Cymblalta        Lyrica        Savella        for first-line treatments. this is
care physicians (PCPs) who see                                  n= 76 PCPs            n= 75 Rheumatologists                   one area where the numbers
at least 10 fibromyalgia patients      Source: Decision Resources
                                                                                                                              are in pharma’s favor. though
per month, only 4% are com-                                                                                                   rheumatologists could benefit
fortable diagnosing it after one                                                                                              from more education—45% of
visit, compared to over 40% of      patients in the care of PCPs take                 more likely to prescribe generics       them need to see a patient two
rheumatologists, according to a     longer to receive their diagnosis,                than branded drugs for patients         times before feeling comfortable
survey from Decision resources      they likely must wait longer for                  with this condition. (Forest/           with a diagnosis—focusing detail
which focused on the emerging       drug treatment.                                   Cypress bioscience’s savella            efforts on the nation’s 4,600
category. “this underscores            Confusion in 
								
To top